Sarepta halts early-stage gene therapy trial for DMD
A stray DNA fragment was found "in connection with routine quality assurance testing" of the plasmids used in the company's gene therapy.
Sarepta Therapeutics’ clinical trial for a gene therapy to treat Duchenne muscular dystrophy has been paused by the Food and Drug Administration because some of the materials used in the treatment weren’t as they should be, the company announced Wednesday.
A stray
